Metformin and CMGC (CDK/MAPK/GSK3/CLK) kinase group. Novel mechanisms to establishing a casual relationship. Inhibición múltiple de quinasas y apoptosis (Abril 2013)

(CDK/MAPK/GSK3/CLK) are a kinase group which regulate proliferation, expression, differentiation, mitosis, cell survival, and apoptosis, among many others.

We found a novel mechanism where a simple molecule as metformin is able to modulate and create a synergy interaction with the kinase group. Reduced doses of chemotherapy with a increased affectivity, less relapse and less resistance to novel treatments were some of our clinical findings in more than one hundred different tumor genotypes.

The use of stronger and specific ativators can increase a fatal outcome in patients depending of tumor grade where metformin is well tolerated.

Find a balance between a stronger and multiple Kinase activators with more efficacy and less side effects will be our next challenge.

Luis Llorente

Oncostop Foundation 

searchcancer@gmail.com

Texto Previo

Futuros Ensayos clínicos con moléculas multifuncionales que bloquean e inhiben cascadas metabólicas claves en la angiogénesis y supervivencia tumoral, conduciendo a la activación de la apoptosis serán realizados dentro de 5 años, terminada la crisis mundial.
Ningún hospital consultado hasta ahora puede permitirse el gasto de una investigación sin subvenciones o patrocinadores.